Multidrug resistance (MDR) significantly restricts the clinical efficacy of gastric cancer (GC) chemotherapy, and it is critical to search novel targets to predict and overcome MDR. Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) has been proved to be correlated with drug resistance in several cancers. The present study revealed that LRIG1 was overexpressed in chemosensitive GC tissues and decreased expression of LRIG1 predicted poor survival in GC patients. We observed that upregulation of LRIG1 enhanced chemosensitivity in GC cells. Interestingly, miR-20a, which was overexpressed in GC MDR cell lines and tissues, was identified Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1), a transmembrane protein, is a pan-ERBB negative regulator that Zhou, Li, Zhou and Jin equally contributed to this study.
inhibits EGFR (epidermal growth factor receptor) signaling by accelerating receptor internalization and degradation in a c-CBLe-dependent manner. [4] [5] [6] Substantial evidence indicates that LRIG1 is involved in tumorigenesis and functions as a tumor suppressor. 6 Low expression of LRIG1 has been associated with poor prognosis in breast, 7, 8 oropharyngeal 9 and nasopharyngeal cancers. 10 Stutz et al (2008) report that overexpression of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity and negatively regulates the oncogenic EGF receptor mutant EGFRvIII. 11 Moreover, LRIG1 downregulation attenuates tumor necrosis factor a (TNFa)-gene expression and confers resistance to Smac mimetics in breast and ovarian cancers. 12 Liu et al (2015) demonstrate that LRIG1 could reverse MDR in glioblastoma, by negatively regulating EGFR and suppressing the expression of ATP-binding cassette, sub-family B member 1 (ABCB1) and ATP-binding cassette sub-family G member 2 (ABCG2). 13 However, the function of LRIG1 in GC MDR remains unclear, and needs to be elucidated.
MicroRNA (miRNA) are small, evolutionarily conserved, non-coding RNA of 18-25 nucleotides in length, which bind to the 3 0 -untranslated regions (3 0 -UTR) of target genes, leading to either target mRNA degradation or protein translation reduction. 14, 15 It was estimated that approximately 30% of human genes and most genetic pathways are regulated through miRNA. 14, 15 As a negative regulator at the posttranscriptional level, miRNA is an important mechanism regulating gene expression. 14, 15 In addition, mounting evidence has shown that miRNA are involved in GC development and progression, including MDR. [16] [17] [18] We thus speculate that dysregulation of LRIG1's regulatory miRNA might be a main cause of its downregulation in MDR of GC.
In the present study, we showed that LRIG1 was overexpressed in chemosensitive GC tissues compared with chemoresistant ones, and decreased expression of LRIG1 predicted poor survival. We further observed that upregulation of LRIG1 enhanced chemosensitivity to various drugs in GC cells. In addition, we demonstrated that miR-20a, which was overexpressed in GC MDR cell lines and tissues, regulated LRIG1 expression by directly targeting its 3 0 -UTR. We also found that inhibition of miR-20a suppressed GC MDR, and upregulation of miR20a showed opposite effects. Moreover, the miR-20a/LRIG1 axis regulated GC cell MDR through EGFR-mediated phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) and MAPK/ERK signaling.
| MATERIALS AND METHODS

| Cell culture and tissue collection
The human GC cell line SGC7901 and its multidrug-resistant variants SGC7901/VCR and SGC7901/ADR were obtained from the State and measured in the LightCycler 480 (Roche, Basel, Switzerland).
GAPDH or U6 snRNA was used as an endogenous control, and an internal control was used to verify that sample loading was equal.
The fold change was calculated by 2 ÀDDCt . All reactions were performed in triplicate.
| Western blotting
Whole-cell lysates were prepared in RIPA buffer (Byotime, Haimen, China), and western blot analysis was performed. 19 The primary antibodies used were anti-LRIG1 (Abcam), anti-EGFR (Cell Signaling), 
| Oligonucleotide construction and transfection
Mimics and inhibitors for has-miR-20a and negative control oligonucleotides were purchased from RiboBio. siRNA and plasmids for LRIG1 and corresponding negative control were obtained from Genechem (Shanghai, China). Target cells were transfected with oligonucleotides using Lipofectamine 2000 Reagent (Invitrogen) according to the manufacturer's instructions.
| In vitro drug sensitivity assay
Drug sensitivity was assessed as described previously. 20 Briefly, 
| Luciferase assay
Plasmids carrying wild-type Luc-LRIG1 or mutant Luc-LRIG1-ß3 0 -UTR were synthesized (GeneCopoeia, Rockville, MD, USA). The luciferase assay was performed as previously described. 22 
| Immunoprecipitation
An immunoprecipitation assay was performed as previously described using an anti-LRIG1 antibody. 23 The total protein was prepared using M-PERTM Mammalian Protein Extraction Reagent (Pierce, Appleton, WI, USA); 10% of chromatin was used as an input control, and a non-specific antibody (anti-IgG, Abcam) served as a negative control. The obtained proteins were subjected to western blotting in an attempt to amplify the LRIG1-binding sites. expression was more frequently present in the chemosensitive GC cases than in the chemoresistant ones ( Figure 2A ,B and Table 1 ).
Moreover, IHC results further confirmed that LRIG1 expression was downregulated in GC tissues compared with adjacent nontumor tissues (Table S2) 
F I G U R E 2 Decreased leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) expression is associated with chemoresistance in gastric cancer (GC).
A, Immunohistochemistry analysis of LRIG1 expression in chemosensitive and chemoresistant GC tissues. B, Expression level of LRIG1 mRNA in chemosensitive and chemoresistant GC tissues was measured using quantitative RT-PCR. GAPDH was used as an internal control and the fold change was calculated by 2 ÀDDCt . *P < .05. C, Expression of LRIG1 in GC cell line SGC7901 and its multidrug resistance variants (MDR) SGC7901/VCR and SGC7901/ADR were examined through western blot analysis. b-actin was used as an internal control. D, Expression level of LRIG mRNA in GC cell line SGC7901 and its MDR variants SGC7901/VCR and SGC7901/ADR were measured using quantitative RT-PCR. GAPDH was used as an internal control. *P < .05, **P < .01 Statistical analysis revealed that LRIG1 expression was inversely correlated with miR-20a expression ( Figure 4G ). These observations suggested that miR-20a and LRIG1 are inversely expressed in GC specimens.
| miR-20a is involved in chemoresistance of gastric cancer cells
To verify the effect of miR-20a on GC drug resistance, we trans- (Table 2 ). Meanwhile, upregulation of miR-20a led to reduced apoptosis ( Figure 5D ). In contrast, inhibition of miR-20a in SGC7901/ADR and SGC7901/VCR cells sensitized drug-resistant cells to chemotherapeutics by increasing the intracellular concentration of ADR ( Table 2 ). Silencing of miR-20a decreased the IC50 values and also markedly raised apoptosis rates ( Figure 5B-D) .
Therefore, these results indicated that miR-20a has a negative effect on GC chemosensitivity.
Because LRIG1 can inhibit GC cell chemoresistance and miR-20a
can post-transcriptionally regulate the expression of LRIG1, we hypothesized that miR-20a-mediated downregulation of LRIG1 directly promotes GC chemoresistance. To address this hypothesis, we first transfected SGC7901 cells with LRIG1 plasmids, and then miR-20a mimic was co-transfected into SGC7901 cells ( Figure 5E ).
In vitro drug sensitivity assay demonstrated that the restoration of miR-20a expression significantly reduced LRIG1-induced GC cell chemosensitivity ( Figure 5F ). Expression level of miR-20a in GC cell line SGC7901 and its multidrug resistance (MDR) variants SGC7901/VCR and SGC7901/ADR. The U6 small nuclear RNA was used as an internal control and the fold change was calculated using 2 ÀDDCt . *P < .05. B, Diagram of LRIG1 3 0 -UTRcontaining reporter construct. Mutations were generated at the predicted miR-20a binding site located in the LRIG1 3 0 -UTR. C, Luciferase activity after the wild-type or mutant reporter plasmids were co-transfected with miR-20a mimic or negative control (NC) in HEK293T and SGC7901 cells. *P < .05, **P < .01, n.s. no significance. D, Expression of LRIG1 mRNA in SGC7901 cells after transfection with miR-20a mimic or mimic control (mimic NC), and SGC7901/ADR and SGC7901/VCR cells transfected with miR-20a inhibitors or inhibitor control (inhibitor NC) were analyzed using quantitative RT-PCR. GAPDH was used as an internal control. *P < .05, **P < .01. E, Expression of LRIG1 protein was analyzed in SGC7901 cells after transfection with miR-20a mimic or mimic NC, and SGC7901/ADR and SGC7901/VCR cells transfected with miR-20a inhibitors or inhibitor NC through western blotting. b-actin served as an internal control. F, Expression of miR-20a in chemosensitive and chemoresistant GC tissues was examined by quantitative RT-PCR. U6 was used as an internal control. **P < .01. G, Statistically significant inverse correlation between miR-20a and LRIG1 mRNA levels in GC specimens (Spearman's correlation analysis, r = À.48; P < .01) induced EGFR depletion may be, at least partially, attributed to an increase in protein degradation by the proteasome. Subsequently, a co-immunoprecipitation method was carried out to determine whether there was a physical interaction between LRIG1 and EGFR molecules. As shown in Figure 6C , EGFR could be specifically coimmunoprecipitated with LRIG1, but not with control IgG, indicating that these 2 proteins were specifically associated with each other in complex. In addition, EGFR expression was detected through IHC in the 47 GC tissues, and statistical analysis revealed that LRIG1 expression was significantly negatively correlated with EGFR levels (Table 3) .
It is well known that EGFR mediated PI3K/AKT and MAPK/ERK pathways play very important roles in GC drug resistance. may act as a tumor suppressor in humans. 33 Reduced expression of LRIG1 has been reported in breast, cervical and skin cancers, as reviewed. 6, 34 The soluble ectodomain of LRIG1 inhibits in vivo growth of EGFRVIII mutant gliomas, and restoration of LRIG1 expression sensitizes glioma cells to chemotherapy. 11 In the present study, we observed that LRIG1 was downregulated in GC tissues, agents. 42 Furthermore, miR-20a enhanced cisplatin resistance of GC by targeting cylindromatosis. 43 This study further confirmed that miR-20a is involved in the MDR of GC, and acts as an oncogenic miRNA.
Currently, the tumor suppressive function of LRIG1 is mainly attributed to its inhibitory effect on EGFR signaling. [4] [5] [6] Over the last decade, it has been shown that LRIG1 binds to EGFR and attenuates EGFR signaling through both receptor degradation and catalytic inhibition. [4] [5] [6] 10 EGFR is a well-studied, versatile signal transducer that is overexpressed in many types of tumor cells, including lung, colon and prostatic carcinoma, and upregulation of EGFR is associated with poor clinical prognosis. 26, 44, 45 EGFR mediates signals that stimulate proliferation, migration and metastasis in many tumor types, and its signal transduction is regulated by stimulatory and inhibitory inputs. 26, 46 Yu et al demonstrate that PI3K/AKT pathway could be inactivated by doxorubicin and etoposide, and wortmannin could increase the sensitivity of GC cells to chemotherapy. 24 Zhang et al demonstrated that miR-939 contributed to chemosensitivity by inhibiting the SLC34A2/Raf/MEK/ERK pathway. 47 The present study showed that the miR-20a/LRIG1 axis might regulate GC cell drug resistance by increasing EGFR activity and through secondary promotion of PI3K/AKT and MAPK/ERK signaling pathways.
In conclusion, the results obtained in the present study reveal that low expression of LRIG1 in GC drug resistance might reflect the increased levels of miR-20a, which could significantly promote MDR in GC. Furthermore, the miR-20a/LRIG1 axis might regulate GC drug resistance through EGFR-mediated PI3K/AKT and MAPK/ERK signaling. The newly identified miR-20a/LRIG1/EGFR link provides a novel potential therapeutic strategy for the future treatment of GC patients with MDR.
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